Apheresis platelets versus pooled platelets – comparison of quality and safety

Česká verze

Authors: H. Lejdarová ^1,2
Authors place of work: Transfuzní a tkáňové oddělení, Fakultní nemocnice Brno ¹; Katedra laboratorních metod, Lékařská fakulta Masarykovy univerzity, Brno ²
Published in the journal: Transfuze Hematol. dnes,22, 2016, No. 4, p. 244-253.
Category: Souhrnné práce, původní práce, kazuistiky

Summary

Platelet transfusions have an important place in haemotherapy thanks to the progress in oncological and intensive care treatment. Apheresis platelets as well as pooled platelets – platelet concentrates derived from whole blood are available in the Czech Republic, although the use of these two product types may vary. There is a widely accepted opinion among clinicians that apheresis platelets are of a higher quality and are safer compared to pooled platelets. Many studies have compared both of these types and these assumptions have not confirmed. This review presents the existing information on apheresis and pooled platelets and compares them from various aspects. The first part of this work describes platelet transfusion products, how they are prepared and stored. The second part compares platelet concentrates from apheresis with platelets derived from whole-blood donations from the aspect of adverse post-transfusion events, risk of alloimmunization and refractoriness.

Key words:
apheresis platelets – pooled platelets – adverse events – alloimmunization – refractoriness

Zdroje

1. Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99: 1–15.

2. Katus MC, Szczepiorkowski ZM, Dumont LJ, Dunbar NM. Safety of platelet transfusion: past, present and future. Vox Sang 2014;107: 103–113.

3. Turek P. Přehled produkce transfuzní služby ČR za rok 2014 (transfuzní přípravky i plazma k frakcionaci). Transfuze a hematologie dnes 2015; 21: 158–160.

4. Pietersz RNI. Pooled platelet concentrates: An alternative to single donor apheresis platelets? Transfusion and apheresis science 2009; 41: 115–119.

5. Van der Meer PF. Platelet concentrates, from whole blood or collec-ted by apheresis? Transfusion and apheresis science 2013; 48: 129–131.

6. Standards for blood banks and transfusion services, 29th edn. Bethesda (MD): AABB Press, 2014.

7. Guide to the preparation, use and quality assurance of blood components, 18th ed. Strasbourg: Council of Europe Pub., 2015.

8. Vyhláška MZ ČR č. 143/2008 Sb., o stanovení bližších požadavků pro zajištění jakosti a bezpečnosti lidské krve a jejích složek (vyhláška o lidské krvi).

9. Doporučení Společnosti pro transfuzní lékařství ČLS JEP č. STL2007_03: Posuzování způsobilosti k dárcovství krve a krevních složek, verze 7, 12.4.2007, dostupné na: http://www.transfuznispolecnost.cz/index.php?page=dokumenty&identifikator_kategorie=DOPORUCENE_POSTUPY.

10. Lozano M, Cid J. Recent advances in platelet processing and storage. ISBT Science series 2016; 11(Suppl. 1): 34–38.

11. Moroff G, AuBuchon JP, Pickard C, Whitley PH, Heaton WA, Holme S. Evaluation of the properties of components prepared and stored after holding of whole blood units for 8 and 24 hours at ambient temperature. Transfusion 2011; 51(Suppl. 1): 7S–14S.

12. Gulliksson H. Platelet storage media. Vox Sang 2014; 107: 205–212.

13. Doporučení Společnosti pro transfuzní lékařství ČLS JEP č. STL2015_11: Skladování a přeprava krve, krevních složek, suroviny pro další výrobu a transfuzních přípravků, verze 1, 2.11.2015, dostupné na: http://www.transfuznispolecnost.cz/index.php?page=dokumenty&identifikator_kategorie=DOPORUCENE_POSTUPY.

14. Tynngård N. Preparation, storage and quality control of platelet concentrates. Transfusion and apheresis science 2009; 41: 97–104.

15. Anderson NA, Gray S, Copplestone JA, et al. A prospective rando-mized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 1997; 7: 33–39.

16. Kluter H, Dorges L, Maass E, Wagner T, Bartels H, Kirchner H. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Ann Haematol 1996; 73: 85–89.

17. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861–1870.

18. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42: 556–566.

19. Gurkan E, Patah PA, Saliba RM, et al. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 461–464.

20. Heddle NM, Arnold DM, Boye D, Webert KE, Resz I, Dumont LJ. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48: 1447–1458.

21. Hess JR, Trachtenberg FL, Assmann SF, et al. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. Vox Sang 2016; publikováno elektronicky 17. května 2016. DOI 10.1111/vox.12411.

22. Penka M, Tesařová E, et al. Hematologie a transfuzní lékařství II. In: Tesařová E. Hemoterapie. 1. vyd. Praha, Grada Publishing, 2012; 131–177.

23. Řeháček V, Masopust J, et al. Transfuzní lékařství. In: Procházková R., Turek P. Potransfuzní reakce. 1. vyd. Praha, Grada Publishing, 2013; 105–118.

24. Tobian AAR, Fuller AK, Uglik K, et al. The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count inkrement. Transfusion 2014; 54: 1523–1529.

25. Scherezenmeier H, Walther-Wenke G, Müller TH, et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47: 644–652.

26. Kopko PM, Warner P, Kresie L, Pancoska C. Methods for the selection of platelet products for alloimmune-refractory patients. Transfusion 2015; 55: 235–244.

27. Vassallo RR, Norris PJ. Can we terminate alloimmune platelet transfusion refractoriness? Transfusion 2016; 56: 19–22.

28. Slichter Sj, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105(10): 4106–4114.

29. Cid J, Harm SK, Yazer MH. Platelet transfusion – the Art and Science of Compromise. Transf Med Hemother 2013; 40: 160–171.

30. McLeod BC, Piehl MR, Sassetti RJ. Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sang 1990; 59: 185–189.

31. Heim MU, Bock M, Kolb HJ, Schleuning M, Mempel W. Intravenous anti-D gammaglobulin for the prevention of rhesus isoimmunization caused by platelet transfusions in patients with malignant diseases. Vox Sang 1992; 62: 156–168.

32. Zeiler T, Wittmann G, Zingsem J, Weisbach V, Zimmermann R, Eckstein R. A dose of 100 IU intravenous anti-D gammaglobulin is effective for the prevention of RhD immunisation after RhD-incompatible single donor platelet transfusion. Vox Sang 1994; 66: 243.

33. Cid J, Carbasse G, Pereira A, et al. Platelet transfusions from D+ donors to D- patients: a 10-year follow-up study of 1014 patients. Transfusion 2011; 51: 1163–1169.

34. Moncharmont P, Barday G, Meyer F. Red blood cell alloimmunisation after platelet transfusion: a 5-year study. Blood Transfusion 2014; 12 (Suppl. 1): 147–148.

35. O’Brien KL, Haspel RL, Uhl L. Anti-D alloimmunization after D-incompatible platelet transfusions: a 14-year single-institution retrospective review. Transfusion 2014; 54: 650–654.

36. Cid J, Lozano M, Ziman A, et al. Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study. British Journal of Hematology 2015; 168: 598–603.

37. Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfusion Medicine Reviews 2003; 17: 57–68.

38. Gunson HH, Stratton F, Phillips PK. The use of modified cells to induce an anti-Rh response. British Journal of Haematology 1971; 21: 683–694

39. Kitazawa J, Nollet K, Morioka H, et al. Non-D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles? Vox Sang 2011; 100: 395–400.

40. Doporučení Společnosti pro transfuzní lékařství ČLS JEP č. STL2015_12: Doporučené postupy pro podání transfuzních přípravků, verze 1, 1.9.2015, dostupné z: http://www.transfuznispolecnost.cz/index.php?page=dokumenty&identifikator_kategorie=DOPORUCENE_POSTUPY.

41. Cooling LL, Downs TA, Butch SH, Davenport RD. Anti-A and anti-B titers in pooled group 0 platelets are comparable to apheresis platelets. Transfusion 2008;48:2106–2113.